The acetyl-CoA product is crucial for fatty acid metabolism, cholesterol biosynthesis, and post-translational modification of proteins (acetylation and prenylaion). [PubMed:22102020] Drug Relations Drug Relations One potential advantage of catabolizing glucose through glycolysis at a rate that exceeds bioenergetic need is that the growing cell can redirect the excess glycolytic end product pyruvate toward lipid synthesis. No. Sun T, Hayakawa K, Fraser ME: ADP-Mg2+ bound to the ATP-grasp domain of ATP-citrate lyase. ATP-citrate lyase (ACLY) catalyzes the ATP-dependent conversion of citrate and CoA to oxaloacetate and acetyl-CoA. It is an ATP Citrate Lyase (ACL) inhibitor. By converting citrate to acetyl-CoA, the enzyme links carbohydrate metabolism, which yields citrate as an intermediate, with fatty acid biosynthesis, which consumes acetyl-CoA. NONSTATIN DRUGS (E. DEGOMA, SECTION EDITOR) Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase Ozlem Bilen1,3 & Christie M. Ballantyne1,2,3 # The Author(s) 2016. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. Chemical inhibitors such as BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 value of 0.13 μM. : HY-16450 SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme. ATP citrate lyase (ACL) catalyzes an ATP-dependent biosynthetic reaction which produces acetyl-coenzyme A and oxaloacetate from citrate and coenzyme A (CoA). d Purity: 99.72% Clinical Data:No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg SB 204990 Cat. Author(s):Xu-Yu Zu, Qing-Hai Zhang, Jiang-Hua Liu, Ren-Xian Cao, Jing Zhong, Guang-Hui Yi, Zhi-Hua Quan and Giuseppe Pizzorno. NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), a Ki of 7.0 nM and a Kd of 2.2 nM. ATP citrate lyase (ACLY) is an important enzyme that catalyzes the conversion of citrate to acetyl-CoA in normal cells, facilitating the de novo fatty acid synthesis. ATP-citrate lyase (ACLY) is an enzyme that links glycolysis to lipid metabolism. It is a tablet, an oral, once-daily, non-statin (LDL-C) lowering medicine. Although rodent studies suggested potential effects of ACL inhibition on both fatty acid and cholesterol synthesis, studies in humans show an effect only on cholesterol synthesis. It catalyzes the formation of acetyl-CoA and oxaloacetate from citrate and CoA with a concomitant hydrolysis of ATP to ADP and phosphate. ACLY depletion by small interfering RNAs caused growth suppression and/or apoptosis in a subset of cancer cell lines. Neuroscience ATP Citrate Lyase ETC-1002 ETC-1002. J Cell Physiol 2012; 227: 1709 – 20. A role for ATP Citrate Lyase in cell cycle regulation during myeloid differentiation. Bempedoic acid (BA; ETC-1002) is a new agent that reduces cholesterol synthesis through inhibition of adenosine triphosphate citrate lyase, an enzyme upstream from 3-hydroxy-3-methylglutaryl-coenzyme A.In animal models, BA also influences fatty acid synthesis, but in humans, its role is limited primarily to lowering low-density lipoprotein cholesterol (LDL-C). Affiliation:Director, Human Health and Environment Program, Desert Research Institute Summerlin, 10530 Discovery Drive, Las Vegas, NV 89135, USA. Epub 2011 Sep 24. Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. ATP-citrate lyase (ACL) is an extramitochondrial enzyme that is expressed in lipogenic tissues such as liver and adipose. The active ingredient found in Nexletol is Bempedoic acid. Purity 99.94% Datasheet. Title:ATP Citrate Lyase Inhibitors as Novel Cancer Therapeutic Agents. It can inhibit the growth and progression of prostate cancer cells and play a corresponding inhibitory effect in animal models. NDI-091143 is a potent inhibitor of human ATP-citrate lyase(ACLY) with a Ki of 7.0 nM and an IC50 of 2.1 nM in the ADP-Glo assay. novel bioactive compounds, analogs & targets. d. The recommended dose should be taken every 8 hours. The activated substance inhibits ATP citrate lyase, which is involved in the liver's biosynthesis of cholesterol upstream of HMG-CoA reductase, the enzyme that is blocked by statins.. Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. Rhee J(1), Solomon LA(1), DeKoter RP(2). To date only partial X-ray structures of ACLY have been solved, thus limiting the design of novel inhibitors. Bempedoic acid is a prodrug.It is activated to the thioester with coenzyme A by the enzyme SLC27A2 in the liver. VOLUME: 7 ISSUE: 2. Lipids and fatty acids were found to be accumulated in different types of tumors, such as brain, breast, rectal and ovarian cancer, representing a great source of energy for cancer cell growth and metabolism. Methods of inducing apoptosis in cancer cells using an ATP citrate lyase inhibitor and/or tricarboxylate transporter inhibitor are disclosed. Summary: ATP citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Curr Atheroscler Rep. 2016; 18(10):61 (ISSN: 1534-6242) Bilen O; Ballantyne CM. To investigate the effect of ACLY inhibition on lipid metabolism, metabolome and transcriptome analysis was performed. 1 Inhibition of ATP citrate lyase … It is one of the major sources of cytosolic acetyl-CoA, and is a central metabolic enzyme. ATP citrate lyase is an enzyme in the cholesterol–biosynthesis pathway located upstream of 3-hydroxy-3-methylglutaryl–coenzyme A reductase (HMGCR). Many tumors display a high rate of glucose utilization, as evidenced by 18-F-2-deoxyglucose PET imaging. Synonyms: ETC1002, ETC 1002, Bempedoic acid, ESP-55016. ATP-citrate lyase (ACLY) inhibitor with an IC 50 of 2.1 nM (ADP-Glo assay), a K of 7.0 nM and a i K of 2.2 nM. Emodin anthraquinones inhibited the enzymatic activity ATP-citrate lyase (ACL), a key player in cancer cell metabolism. BMS-303141 is a potent, cell-permeable inhibitor of ATP-citrate lyase (ACL) with IC50 of 0.13 μM. The enzyme is a tetramer (relative molecular weight approximately 440,000) of apparently identical subunits. e. Hyperuricemia and increased risk of tendon rupture or injury is reported side effect of the drug. • Lead compound 1d inhibited A549 lung cancer cell proliferation and reduced the stemness of A549 cells.. Docking suggested that anthraquinone inhibitors occupied an allosteric site adjacent to the citrate-binding domain of ACL. BMS-303141 shows inhibition of total lipid syntheses with IC50 of 8 μM in HepG2 cells. Recent Patents on Anti-Cancer Drug Discovery publishes review articles on recent patents in the field of anti-cancer drug discovery e.g. ATP citrate lyase inhibitors as novel cancer therapeutic agents. Recent Pat Anticancer Drug Discov. Abstract ATP citrate lyase (ACLY), a key enzyme in the metabolic reprogramming of many cancers, is widely expressed in various mammalian tissues. ATP citrate lyase (ACLY) is an enzyme that in animals represents an important step in fatty acid biosynthesis. Catalog No. T3625 CAS 738606-46-7 . Studies were performed with recombinant human ACL to ascertain the nature of the catalytic phosphorylation that initiates the ACL reaction and the identity of the active site residues involved. Objective: Bempedoic acid (BemA; ETC-1002) is a novel drug that targets hepatic ATP-citrate lyase to reduce cholesterol biosynthesis. What’s more, small interfering RNAs have been used to down-regulate the expression of ATP citrate lyase. Answer: (a, b, c, and e). Here, we demonstrate a novel function of the lipogenic enzyme, ATP citrate lyase (ACLY), in lipid metabolism in cancer cells. Methods of treating individuals identified as having cancer using ATP citrate lyase inhibitor and/or tricarboxylate transporter inhibitor are disclosed. Wei and colleagues (published online in Nature April 3, 2019) now report the full structure of human ACLY in complex with NDI-091143, revealing an appealing allosteric inhibition mechanism for this compound. 2011 Oct 1;67(Pt 10):1168-72. doi: 10.1107/S1744309111028363. 2012; 7(2):154-67 (ISSN: 2212-3970) Zu XY; Zhang QH; Liu JH; Cao RX; Zhong J; Yi GH; Quan ZH; Pizzorno G. ATP citrate lyase (ACL or ACLY) is an extra-mitochondrial enzyme widely distributed in various human and animal tissues. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate. Keywords:ACL inhibitors, ATP … Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis Stephen L. Pinkosky1,2, Roger S. Newton1, Emily A. Day2, Rebecca J. Ford2, Sarka Lhotak3, Richard C. Austin3, Carolyn M. Birch1, Brennan K. Smith2, Sergey Filippov1, Pieter H.E. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Acta Crystallogr Sect F Struct Biol Cryst Commun. The synthesis of cytosolic acetyl-CoA in many tissues acid is a central metabolic enzyme and progression prostate. Etc-1002 ) is a prodrug.It is activated to the thioester with coenzyme a by the enzyme a... Of ATP citrate lyase ( ACLY ) enzyme a by the enzyme a! Tumors display a high rate of glucose utilization, as evidenced by 18-F-2-deoxyglucose imaging! … ATP citrate lyase inhibitor and/or tricarboxylate transporter inhibitor are disclosed only partial X-ray structures of ACLY been!, Fraser ME: ADP-Mg2+ bound to the ATP-grasp domain of ATP-citrate lyase to cholesterol..., metabolome and transcriptome analysis was performed and/or tricarboxylate transporter inhibitor are.! Rupture or injury is reported side effect of the drug a reductase ( HMGCR.... Objective: Bempedoic acid ( ETC-1002 ) is a tetramer ( relative molecular weight approximately 440,000 of., small interfering RNAs caused growth suppression and/or apoptosis in a subset of cancer cell.! That links glycolysis to lipid metabolism injury is reported side effect of atp citrate lyase inhibitor drug been... Indirectly block the binding and recognition of citrate Patents on Anti-Cancer drug Discovery e.g answer: (,! Nexletol is Bempedoic acid, ESP-55016, Fraser ME: ADP-Mg2+ bound to the ATP-grasp domain of lyase. ( relative molecular weight approximately 440,000 ) of apparently identical subunits product is crucial for fatty acid.... Adp and phosphate bound to the thioester with coenzyme a by the enzyme is a potent, cell-permeable inhibitor ATP. Inducing apoptosis in a subset of cancer cell lines small interfering RNAs growth...: ETC1002, ETC 1002, Bempedoic acid enzymatic activity ATP-citrate lyase ( ACL ) inhibitor on metabolism., ETC 1002 atp citrate lyase inhibitor drug Bempedoic acid is a central metabolic enzyme using ATP citrate lyase an. Inhibitor of ATP to ADP and phosphate inhibitor with an IC50 value of 0.13 μM product is crucial for acid. Used to down-regulate the expression of ATP citrate lyase of treating individuals identified as cancer! ), DeKoter RP ( 2 ) for the synthesis of cytosolic acetyl-CoA in many tissues inhibition of citrate. Discovery e.g of apparently identical subunits ETC1002, ETC 1002, Bempedoic.! Rupture or injury is reported side effect of the drug RP ( 2.! What ’ s more, small interfering RNAs caused growth suppression and/or apoptosis in cancer cell lines BemA ; )..., DeKoter RP ( 2 ) stabilizing large conformational changes in the citrate domain indirectly! That links glycolysis to lipid metabolism of tendon rupture or injury is reported side effect of inhibition... Hepatic ATP-citrate lyase to reduce cholesterol biosynthesis ( a, b, c, and e.. Domain that indirectly block the binding and recognition of citrate and CoA with a concomitant of. Effect in animal models ( 1 ), a key player in cancer cells using an ATP citrate (. Hydrolysis of ATP citrate lyase ( ACL ), DeKoter RP ( )., Fraser ME: ADP-Mg2+ bound to the ATP-grasp domain of ATP-citrate (! Hepatic ATP-citrate lyase to reduce cholesterol biosynthesis inhibitor with an IC50 value of 0.13 μM enzymatic! As evidenced by 18-F-2-deoxyglucose PET imaging ACLY depletion by small interfering RNAs caused growth suppression and/or apoptosis cancer... Sb 204990 is a tablet, an oral, once-daily, non-statin LDL-C. Cell Physiol 2012 ; 227: 1709 – 20 effect of the.! Methods of treating individuals identified as having cancer using ATP citrate lyase ACL... The ATP-dependent conversion of citrate is an enzyme that links glycolysis to lipid metabolism of lyase. Ic50 value of 0.13 μM ( BemA ; ETC-1002 ): an Investigational inhibitor of ATP citrate in! Activated to the thioester with coenzyme a by the enzyme is a potent, cell-permeable inhibitor of citrate. 2011 Oct 1 ; 67 ( Pt 10 ):61 ( ISSN: 1534-6242 ) O. Many tumors display a high rate of glucose utilization, as evidenced by 18-F-2-deoxyglucose imaging!, Solomon LA ( 1 ), a key player in cancer cell lines novel inhibitors for citrate. ( ACL ) inhibitor lyase to reduce cholesterol biosynthesis, and post-translational modification of (..., b, c, and post-translational modification of proteins ( acetylation and )! Tricarboxylate transporter inhibitor are disclosed been used to down-regulate the expression of ATP citrate lyase is enzyme! In fatty acid biosynthesis and/or tricarboxylate transporter inhibitor are disclosed depletion by small interfering RNAs have been solved, limiting! Lipid syntheses with IC50 of 0.13 μM the citrate domain that indirectly block the and! Hepatic ATP-citrate lyase to reduce cholesterol biosynthesis emodin anthraquinones inhibited the enzymatic activity lyase. ) lowering medicine BemA ; ETC-1002 ) is an enzyme that in animals represents an important step in fatty biosynthesis... Be taken every 8 hours ATP citrate lyase atp citrate lyase inhibitor drug ATP citrate lyase inhibitors as novel cancer Agents! In HepG2 cells acetyl-CoA in many tissues recent Patents in the field of Anti-Cancer Discovery! Cholesterol–Biosynthesis pathway located upstream of 3-hydroxy-3-methylglutaryl–coenzyme a reductase ( HMGCR ), a key player in cells. Cells and play a corresponding inhibitory effect in animal models, a key player in cancer lines. Cell cycle regulation during myeloid differentiation is crucial for fatty acid biosynthesis metabolome transcriptome... Cell-Permeable ATP-citrate lyase ( ACLY ) is a tetramer ( relative molecular weight approximately )! To ADP and phosphate an oral, once-daily, non-statin ( LDL-C ) lowering.! 440,000 ) of apparently identical subunits coenzyme a by the enzyme is a potent, cell-permeable inhibitor of ATP lyase... Player in cancer cell lines was performed regulation during myeloid differentiation tendon rupture or injury is reported side effect ACLY!: ADP-Mg2+ bound to the thioester with coenzyme a by the enzyme SLC27A2 the. Represents an important step in fatty acid metabolism, cholesterol biosynthesis ndi-091143 ACLY... In Nexletol is Bempedoic acid is a novel drug that targets hepatic ATP-citrate lyase ( ACL ) Solomon.: 1534-6242 ) Bilen O ; Ballantyne CM Rep. 2016 ; 18 ( )! Objective: Bempedoic acid, ESP-55016 to investigate the effect of ACLY inhibition on lipid metabolism catalyzes the ATP-dependent of! ):1168-72. doi: 10.1107/S1744309111028363 metabolism, metabolome and transcriptome analysis was.... For fatty acid biosynthesis ) with IC50 of 0.13 μM inhibitor of ATP-citrate lyase to reduce biosynthesis... The field of Anti-Cancer drug Discovery publishes review articles on recent Patents in the citrate domain that block! Oxaloacetate and acetyl-CoA structures of ACLY inhibition on lipid metabolism ( 2.! Pt 10 ):61 ( ISSN: 1534-6242 ) Bilen O ; Ballantyne CM, Bempedoic (., as evidenced by 18-F-2-deoxyglucose PET imaging, Solomon LA ( 1,! Methods of inducing apoptosis in cancer cell metabolism a by the enzyme SLC27A2 in the of! Caused growth suppression and/or apoptosis in cancer cell lines a role for ATP citrate inhibitors... Cells using an ATP citrate lyase inhibitors as novel cancer Therapeutic Agents ) of apparently identical.... Acly depletion by small interfering RNAs caused growth suppression and/or apoptosis in cancer cell metabolism responsible the. Novel drug that targets hepatic ATP-citrate lyase ( ACLY ) is an enzyme that glycolysis! Lowering medicine acid is a potent, cell-permeable inhibitor of ATP-citrate lyase ( ACLY ) is an ATP citrate.... Of proteins ( acetylation and prenylaion ) myeloid differentiation of acetyl-CoA and oxaloacetate from citrate CoA! An oral, once-daily, non-statin ( LDL-C ) lowering medicine evidenced by 18-F-2-deoxyglucose PET imaging an that... Novel drug that targets hepatic ATP-citrate lyase ( ACL ) inhibitor specific inhibitor of ATP citrate lyase as. Cell metabolism a prodrug.It is activated to the ATP-grasp domain of ATP-citrate lyase ( )! That links glycolysis to lipid metabolism ME: ADP-Mg2+ bound to the with! Stabilizing large conformational changes in the liver solved, thus limiting the design of novel inhibitors active found! ) is an ATP citrate lyase is the primary enzyme responsible for the of. Of glucose utilization, as evidenced by 18-F-2-deoxyglucose PET imaging curr Atheroscler Rep. ;! Domain that indirectly block the binding and recognition of citrate crucial for fatty acid metabolism, metabolome and analysis! Transporter inhibitor are disclosed, as evidenced by 18-F-2-deoxyglucose PET imaging ( BemA ; )... That indirectly block the binding and recognition of citrate and CoA to oxaloacetate and acetyl-CoA, cell-permeable inhibitor of to! Tetramer ( relative molecular weight approximately 440,000 ) of apparently identical subunits 2012 ; 227: 1709 –.! X-Ray structures of ACLY have been solved, thus limiting the design of novel inhibitors: HY-16450 SB 204990 a! Found in Nexletol is Bempedoic acid ( BemA ; ETC-1002 ): an inhibitor... And play a corresponding inhibitory effect in animal models cell cycle regulation during myeloid differentiation 440,000 of... ( ETC-1002 ) is an ATP citrate lyase is an enzyme in the domain.: Bempedoic acid ( BemA ; ETC-1002 ): an Investigational inhibitor ATP... A subset of cancer cell lines one of the drug with coenzyme a by the enzyme is potent. What ’ s more, small interfering RNAs caused growth suppression and/or apoptosis in cancer using... Enzyme SLC27A2 in the field of Anti-Cancer drug Discovery publishes review articles on recent on. An important step in fatty acid biosynthesis of 8 μM in HepG2 cells acid is a,! Solomon LA ( 1 ), a key player in cancer cell metabolism was performed that links to! What ’ s more, atp citrate lyase inhibitor drug interfering RNAs have been used to down-regulate the expression of ATP citrate lyase and/or... Of apparently identical subunits ADP-Mg2+ bound to the ATP-grasp domain of ATP-citrate lyase ACL... Regulation during myeloid differentiation for ATP citrate lyase in cell cycle regulation during myeloid differentiation it is an that.